Sign In  |  Register  |  About Livermore  |  Contact Us

Livermore, CA
September 01, 2020 1:25pm
7-Day Forecast | Traffic

  • Search Hotels in Livermore

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanoviricides Inc (NY: NNVC )

1.340 +0.060 (+4.69%)
Official Closing Price Updated: 8:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanoviricides Inc

< Previous 1 2 3 4 5 6 7 Next >
NanoViricides Patents Its Antiviral Nanotechnology for COVID-19, Continuing Its Development of Potentially Broad-Spectrum Drugs That Are Expected To Be Effective Even Against Emerging Variants
This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Catalyst Biosciences, Inc. (NASDAQ: CBIO) gained 234.2% to close at $1.27 after the company announced it sold its complement portfolio for $60 million. 
Via Benzinga
NanoViricides Starts Drug Development Program For Recent Cases Of Unexplained Pediatric Hepatitis
Via Benzinga
30 Stocks Moving In Monday's Mid-Day Session
Gainers Evolve Transition Infrastructure LP (NYSE: SNMP) shares rose 29.2% to $0.6699 after jumping around 14% on Friday. 
Via Benzinga
Mid-Morning Market Update: Markets Mixed; Broadcom In Talks To Buy VMWare
U.S. stocks traded mixed this morning, with the Dow Jones gaining around 250 points on Monday. 
Via Benzinga
24 Stocks Moving in Monday's Pre-Market Session
Gainers Genocea Biosciences, Inc. (NASDAQ: GNCA) shares rose 33.8% to $0.2795 in pre-market trading after declining around 5% on Friday. 
Via Benzinga
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year. 
Via Benzinga
The Week Ahead In Biotech (May 22-28): Verrica, Bristol-Myers Squibb FDA Decisions, Medtronic Earnings, Conference Presentations & More
Biotech stocks advanced in the week ending May 22, defying the broader market retreat. The defensive nature of the industry and stock-specific moves lent support. 
Via Benzinga
71 Biggest Movers From Yesterday
Gainers NeuroMetrix, Inc. (NASDAQ: NURO) shares jumped 76.3% to close at $5.50 on Thursday after the company announced the FDA has granted De Novo authorization to market the Quell neuromodulation... 
Via Benzinga
CDC Looking Into 180 Cases Of Unexplained Pediatric Acute Hepatitis: CNBC
The Centers for Disease Control and Prevention is now investigating 180 cases of children who suddenly developed severe hepatitis across 36 states and territories, an increase of 71 cases since the... 
Via Benzinga
NanoViricides Has Filed Quarterly Report for Period Ending March 31, 2022 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Progressing Further for Clinical Trials Application
SHELTON, CT / ACCESSWIRE / May 17, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NanoViricides Reports that It Has Begun Drug Development to Combat Recent Cases of Severe Pediatric Hepatitis
SHELTON, CT / ACCESSWIRE / May 16, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
From NanoViricides, Inc.
Via AccessWire
Exposures COVID-19
NanoViricides Provides Update On NV-CoV-2 Coronavirus Drug Candidate Program
SHELTON, CT / ACCESSWIRE / April 25, 2022 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
From NanoViricides, Inc.
Via AccessWire
Exposures COVID-19
Pharmaceutical Companies Are Reportedly Refocusing On Mysterious Rise In Shingles Infections As COVID Declines
Photo Credit: Photo by CDC & Klara Kulikova This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be... 
Via Benzinga
Does the FDA Rollback Of Regeneron And Eli Lilly COVID Treatment EUAs Signal A Need To Look Beyond Monoclonal Antibodies? NanoViricides, Inc. Looks To Meet This Need With A New Approach
Photo credit: Marcelo Leal and Kate Hliznitsova on Unsplash This post contains sponsored advertising content. This content is for informational purposes only and is not intended... 
Via Benzinga
27 Stocks Moving in Monday's Pre-Market Session
Gainers Mullen Automotive, Inc. (NASDAQ: MULN) rose 45.4% to $1.00 in pre-market trading after the company reported progress on solid-state polymer battery pack development.... 
Via Benzinga
NanoViricides Has Filed Quarterly Report for Period Ending December 31, 2021 - Has Sufficient Cash, NV-CoV-2 Coronavirus Drug Candidate Clinical Trials Application Ready
SHELTON, CT / ACCESSWIRE / February 15, 2022 / NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
How Many Boosters Will It Take? A Global Population Beset By Pandemic Fatigue Wants A More Permanent Solution
Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. 
Via Benzinga
Booster Shots Might Not Be Enough to Beat Omicron, According to Some Nanotech Experts
Image provided by Pixabay This post contains sponsored advertising content. This content is for informational purposes only and not intended to be investing advice. As the threat... 
Via Benzinga
NanoViricides Attempts to Leverage Decades of Combined Pharmaceutical and Biotech Experience To Bring Broad-Spectrum COVID-19 Antiviral to Market
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
NanoViricides Says Its Nanomedicine Tech Could Be the Key To Defeating Omicron and Other COVID-19 Variants
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
Exposures COVID-19
These Biotech Companies Are Attempting to Use Improved Antibody Technology in the Fight To Eradicate COVID-19
Image provided by Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of... 
Via Benzinga
NanoViricides Has Filed Quarterly Report for Period Ending September 30, 2021 - Has Sufficient Cash, Coronavirus Drug Candidate Moving Towards Clinical Trials
SHELTON, CT / ACCESSWIRE / November 16, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel... 
From NanoViricides, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
EXCLUSIVE: NanoViricides Completes Oral Gummies, Lung Inhalation Formulations For COVID-19 Treatment
NanoViricides, Inc. (NYSE: NNVC) announced Monday it has developed an oral gummies formulation of its COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized... 
Via Benzinga
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
Welcome back, trader! We're getting right into the thick of it this week with a look at the biggest pre-market stock movers for Monday! 
Via InvestorPlace
NanoViricides Completes Oral Gummies and Lung Inhalation Formulations Development for its Non-Mutagenic, Safe, Broad-Spectrum COVID-19 Clinical Drug Candidate, NV-CoV-2
SHELTON, CT / ACCESSWIRE / November 15, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel... 
From NanoViricides, Inc.
Via AccessWire
Exposures COVID-19 Product Safety
EXCLUSIVE: NanoViricides Develops Chewable Pills, Lung Inhalation Formulations For COVID-19 Candidate
NanoViricides Inc (NYSE: NNVC) has developed oral gummies formulations of its Pan-Coronavirus COVID-19 Drug Candidate NV-CoV-2 to benefit non-hospitalized patients. What... 
Via Benzinga
Exposures COVID-19
Todos Medical Says It Wants to Outfox COVID-19 & Cancer Along With Rivals Pfizer & Merck With New Theranostic Approach
Photo by Artem Podrez from Pexels The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Exposures COVID-19
Are Pfizer, Moderna, J&J Booster Shots a Panacea? This Company Says Its Broad-Spectrum Drugs to Fight COVID-19 Would Help End the Pandemic
Photo by Steven Cornfield on Unsplash The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial... 
Via Benzinga
Exposures COVID-19
NanoViricides, Inc. Has Filed its Annual Report: Coronavirus Drug Program Rapidly Moving Towards Clinical Stage
SHELTON, CT / ACCESSWIRE / October 13, 2021 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed its Annual Report on Form 10-K for the fiscal year ending June 30, 2021... 
From NanoViricides, Inc.
Via AccessWire
Topics Intellectual Property Regulatory Compliance
Exposures COVID-19 Intellectual Property Legal
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 Livermore.com & California Media Partners, LLC. All rights reserved.